Nicox to co-promote eye drug with Bausch + Lomb in the US

Fri Aug 8, 2014 1:46am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

PARIS Aug 8 (Reuters) - French pharmaceutical firm Nicox said it had notified Bausch + Lomb, a division of Valeant Pharmaceuticals, that it would exercise its option to co-promote eye drug latanoprostene bunod in the United States.

Nicox and B+L will now start negotiating a co-promotion agreement which will be signed at a later stage, Nicox said in a statement on Friday. (Reporting by Natalie Huet; Editing by Stephen Coates)